Send Cellectar Biosciences: Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma to a friend:
Friend's E-mail Address:

Why do we need to know your name and e-mail address? We’re not trying to be nosy. We just want to let your friend know who to thank for sharing with them.

Your Name:

Your E-mail Address:


Close Window